Showing results (231-240 of 263) with videos related to

Sort By:
Pageof 27
Blood|January 17, 2013
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemiaEric Jourdan, Nicolas Boissel, Sylvie Chevret, et al.
Leukemia|February 21, 2020
Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative StudySabine Kayser, Ramy Rahmé, David Martínez-Cuadrón, et al.
Blood|December 19, 2009
Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experienceLionel Adès, Agnes Guerci, Emmanuel Raffoux, et al.
Blood|April 18, 2014
Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemiaKheira Beldjord, Sylvie Chevret, Vahid Asnafi, et al.
Leukemia|January 30, 2020
Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantationRathana Kim, Nicolas Boissel, Aurore Touzart, et al.
Blood Advances|February 11, 2021
Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohortEdmond Chiche, Ramy Rahmé, Sarah Bertoli, et al.
Leukemia|June 26, 2020
Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapyMarco Cerrano, Matthieu Duchmann, Rathana Kim, et al.
Blood Advances|May 8, 2020
Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study resultsClaude Gardin, Cécile Pautas, Elise Fournier, et al.
Blood|May 28, 2009
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or olderJean-Luc Harousseau, Giovanni Martinelli, Wieslaw W Jedrzejczak, et al.
Blood|April 21, 2021
Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA studyMatthieu Duchmann, Jean-Baptiste Micol, Nicolas Duployez, et al.
Pageof 27